Ismael Martin, DO
Pulmonary Disease · Naples, FLNPI 1750353322
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 409 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 37 manufacturers, the largest accounting for just 16.9% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $3,416 and has fallen 58.7% since, to $1,412 in 2025.
Across 409 payments — averaging $22.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$2K
- GSK$1K
- Boehringer Ingelheim$1K
- Mylan Specialty L.p.$573
- Actelion Pharmaceuticals US, Inc.$529
- Sanofi$312
- plus $4K from 31 others
What the payments were for
- Food & beverage$9,288100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 72 | $1,566 |
| GSK | 68 | $1,317 |
| Boehringer Ingelheim | 35 | $1,043 |
| Mylan Specialty L.p. | 31 | $573 |
| Actelion Pharmaceuticals US, Inc. | 18 | $529 |
| Sanofi | 12 | $312 |
| Amgen | 12 | $309 |
| Genentech USA, Inc. | 20 | $307 |
| Johnson & Johnson(2 entities) | 5 | $270 |
| Grifols USA, LLC | 12 | $254 |
| Regeneron Healthcare Solutions, Inc. | 12 | $254 |
| Insmed, Inc. | 10 | $224 |
| Inspire Medical Systems, Inc. | 3 | $223 |
| Paratek Pharmaceuticals, Inc. | 4 | $170 |
| Mallinckrodt Hospital Products Inc. | 3 | $155 |
| Takeda Pharmaceuticals U.S.A., Inc. | 7 | $144 |
| Philips North America LLC | 7 | $134 |
| Circassia Inc. | 8 | $133 |
| La Jolla Pharmaceutical Company | 2 | $131 |
| Sunovion Pharmaceuticals Inc. | 11 | $123 |
| Novartis | 6 | $122 |
| Jazz Pharmaceuticals Inc. | 7 | $118 |
| Merck | 1 | $112 |
| Bayer | 7 | $103 |
| Shire North American Group Inc | 5 | $102 |
| United Therapeutics Corporation | 3 | $88 |
| Gilead | 4 | $69 |
| Advanced Respiratory, Inc | 3 | $67 |
| Viatris Specialty LLC | 3 | $63 |
| Electromed, Inc. | 6 | $57 |
| Pulmonx Corporation | 2 | $51 |
| Verona Pharma, Inc. | 3 | $48 |
| Teva Pharmaceuticals USA, Inc. | 3 | $38 |
| Axsome Therapeutics, Inc. | 1 | $31 |
| Phadia US Inc. | 1 | $18 |
| Tactile Systems Technology Inc | 1 | $15 |
| Inogen, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- OFEV$244
- TRELEGY ELLIPTA$237
- OPSUMIT$236
- TEZSPIRE$216
- MONARCH$146
- GIAPREZA$116
- NUZYRA$113
- STEGLATRO$112
- Inspire Upper Airway Stimulation System$108
- ACTHAR$102
How this compares
$9,288 in reported general payments places this provider in the 75th percentile of 953 pulmonary disease providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 150 | $123,726 |
| Breo ElliptaFluticasone/Vilanterol | 61 | $34,250 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 51 | $28,021 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 27 | $20,833 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 20 | $12,527 |
| EliquisApixaban | 12 | $6,949 |
| Bevespi AerosphereGlycopyrrolate/Formoterol Fum | 12 | $5,180 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 50 | $1,623 |
| Pantoprazole Sodium | 34 | $382 |
| Montelukast Sodium | 40 | $375 |
| Azithromycin | 25 | $250 |
| Fluticasone Propionate | 17 | $243 |
| Prednisone | 58 | $169 |
| Omeprazole | 16 | $163 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta | $1,317 | $170,503231 claims |
| Boehringer IngelheimStiolto Respimat | $1,043 | $28,02151 claims |
| AstraZenecaBreztri Aerosphere, Bevespi Aerosphere | $1,566 | $26,01339 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 953 pulmonary disease providers in Florida.
Other pulmonary disease in Naples
- Edward SalernoNaples$154K
- Franck RahaghiWeston$1.2M
- Michael OttEglin Afb$909K
- Ali JiwaniOrlando$859K
- Anas HadehWeston$800K
- Jennifer FultonJacksonville$665K
- Ricardo Restrepo-JaramilloTampa$555K
- Mark RumbakTampa$528K
- Jose Soto SotoJacksonville$504K
- Javier Perez FernandezMiami$496K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.